Back to Search Start Over

Data from Implementation of HPV-based Cervical Cancer Screening Combined with Self-sampling Using a Midwifery Network Across Rural Greece: The GRECOSELF Study

Authors :
Kostas Stamatopoulos
Anastasia Hadzidimitriou
Andreas M. Kaufmann
George Adonakis
Minas Paschopoulos
Ekaterini Chatzaki
Violetta Vaitsi
Athanasia Chronopoulou
Georgia Agelena
Vaia Piha
Theoni Truva
Despina Halatsi
Paraskevi Zempili
George Koukoulis
Ioannis Kalogiannidis
George Michail
George O. Decavalas
Theodoros Panoskaltsis
Efthimios Deligeoroglou
George Manidakis
Antonis Makrigiannakis
Emmanuel N. Kontomanolis
Vasilis Lymberis
Thomas Vrekoussis
Theodoros Stefos
Antonios Garas
Polyxeni Vanakara
Alexandros Daponte
Maria Ntoula
Ioannis Venizelos
Stamatia Aggelidou
Evangelia Katsiki
Alkmini Skenderi
Viktoria Moschaki
Theodoros Moysiadis
Anastasia Kitsou
Konstantinos Pasentsis
Evangelia Mouchtaropoulou
Athena Tsertanidou
Kimon Chatzistamatiou
Theodoros Agorastos
Publication Year :
2023
Publisher :
American Association for Cancer Research (AACR), 2023.

Abstract

Self-sampling for human papillomavirus (HPV) testing is an alternative to physician sampling particularly for cervical cancer screening nonattenders. The GRECOSELF study is a nationwide observational cross-sectional study aiming to suggest a way to implement HPV-DNA testing in conjunction with self-sampling for cervical cancer screening in Greece, utilizing a midwifery network. Women residing in remote areas of Greece were approached by midwives, of a nationwide network, and were provided with a self-collection kit (dry swab) for cervicovaginal sampling and asked to answer a questionnaire about their cervical cancer screening history. Each sample was tested for high-risk (hr) HPV with the Cobas HPV test. HrHPV-Positive women were referred to undergo colposcopy and, if needed, treatment according to colposcopy/biopsy results. Between May 2016 and November 2018, 13,111 women were recruited. Of these, 12,787 women gave valid answers in the study questionnaire and had valid HPV-DNA results; hrHPV prevalence was 8.3%; high-grade cervical/vaginal disease or cancer prevalence was 0.6%. HrHPV positivity rate decreased with age from 20.7% for women aged 25–29 years to 5.1% for women aged 50–60 years. Positive predictive value for hrHPV testing and for HPV16/18 genotyping ranged from 5.0% to 11.6% and from 11.8% to 27.0%, respectively, in different age groups. Compliance to colposcopy referral rate ranged from 68.6% (for women 25–29) to 76.3% (for women 40–49). For women residing in remote areas of Greece, the detection of hrHPV DNA with the Cobas HPV test, on self-collected cervicovaginal samples using dry cotton swabs, which are provided by visiting midwives, is a promising method for cervical cancer secondary prevention.

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........3d8d3fc0fb0b5464ce63ae5c0e7db63c
Full Text :
https://doi.org/10.1158/1940-6207.c.6547463.v1